Figure 1: Cell-binding assays with a defined α v integrin phage ligand and phage-cell–binding optimization with BRASIL. To test the selection method, we compared 21 phage clones randomly chosen ...

Dr. Rainero and her team will study how blocking a2b1 integrin affects breast cancer growth and spread. These studies will be conducted using lab-grown cells, patient samples, and animal models ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

anti-VEGF agent by binding to integrin receptors; and transferrin, which targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. These features will ...

CloseCurlyDoubleQuote; OCU200 is a recombinant fusion protein that consists of two parts connected by a linker: tumstatin, the active component, acts as an anti-inflammatory, anti-VEGF agent by ...